UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 4)

Under the Securities Exchange Act of 1934

Cellectar Biosciences, Inc. (Name of Issuer)

Common Shares (Title of Class of Securities)

15117F500 (CUSIP Number)

December 31, 2023 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
NYC#: 139632.2

1.			ORTING PERSONS CATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Rosalind Advisors, Inc.			
2.	CHECK TH (see instruction (a) □ (b) □		PROPRIATE BOX IF A MEMBER OF A GROUP	
3.	SEC USE O	NLY		
4.	CITIZENSH	IIP OF	R PLACE OF ORGANIZATION	
	ONTARIO,	CANA	ADA	
		5.	SOLE VOTING POWER	
			0	
		6.	SHARED VOTING POWER	
NUMBER OF SHARES BENEFICIALLY OWNED BY		7.	1,488,400 shares of Common Stock 6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock 3,171,723 shares of Common Stock issuable upon exercise of warrants SOLE DISPOSITIVE POWER	
REP	EACH ORTING		0	
PERS	ON WITH	8.	SHARED DISPOSITIVE POWER	
			1,488,400 shares of Common Stock 6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock 3,171,723 shares of Common Stock issuable upon exercise of warrants	
9.	AGGREGA	TE Al	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	6,676,933 s	hares	of Common Stock of Common Stock issuable upon conversion of Preferred Stock of Common Stock issuable upon exercise of warrants	
10.	CHECK IF (see instruction		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11.	PERCENT (OF CL	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	9.9% <u>1</u>			
12.	TYPE OF R	EPOR	RTING PERSON (see instructions)	
	CO			
				_

This percentage is calculated based upon 30,452,042 shares of the Issuer's common stock outstanding as of January 31, 2024 in accordance with Issuer's 10-Q filed on February 2, 2024. However, as more fully described in Item 3, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).

1.	NAMES OF	REPORTING PERSONS
	I.R.S. IDEN	TIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Steven Salar	non
2.	CHECK TH (see instruction (a) □ (b) □	E APPROPRIATE BOX IF A MEMBER OF A GROUP ions)
3.	SEC USE O	NLY
4.	CITIZENSH	IIP OR PLACE OF ORGANIZATION
	ONTARIO,	CANADA
	ONTAKIO,	CANADA
		5. SOLE VOTING POWER
		0
		6. SHARED VOTING POWER
1,488,400 s 6,676,933 s 3,171,723 s		1,488,400 shares of Common Stock 6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock 3,171,723 shares of Common Stock issuable upon exercise of warrants 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,488,400 shares of Common Stock 6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock 3,171,723 Shares of Common Stock issuable upon exercise of warrants TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON hares of Common Stock issuable upon conversion of Preferred Stock hares of Common Stock issuable upon exercise of warrants THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
	(see instructi	ions)
11.	PERCENT (OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	9.9%	
12.	TYPE OF R	EPORTING PERSON (see instructions)
	IN	
NYC#:	139632.2	

1.		REPORTING PERSONS	
	I.R.S. IDEN	TIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Gilad Aharo	n	
2.		E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(see instruct	ons)	
	(b) \Box		
3.	SEC USE O	NLY	
4.	CITIZENSE	IIP OR PLACE OF ORGANIZATION	
	ONTARIO	CONTRA	
	ONTARIO,	CANADA	
		5. SOLE VOTING POWER	
		0	
		6. SHARED VOTING POWER	
NUN	MBER OF		
SF	HARES	1,488,400 shares of Common Stock 6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock	
	FICIALLY NED BY	3,171,723 shares of Common Stock issuable upon exercise of warrants	
E	EACH	7. SOLE DISPOSITIVE POWER	
	ORTING ON WITH	3,900 shares of Common Stock	
LIND	011 11111	8. SHARED DISPOSITIVE POWER	
		1,488,400 shares of Common Stock	
		6,676,933 shares of Common Stock issuable upon conversion of Preferred Stock	
		3,171,723 Shares of Common Stock issuable upon exercise of warrants	
9.	AGGREGA	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1 400 400 -1		
		ares of Common Stock hares of Common Stock issuable upon conversion of Preferred Stock	
		ares of Common Stock issuable upon exercise of warrants	
10.	CHECK IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(see instruct		
11.	PERCENT (OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	9.9%1		
12.		EPORTING PERSON (see instructions)	
	IN		
	IIN		
CUSII	No. 15117F :	500 13G/A	Page 5 of 10 Pages
	NAMES OF	DEDODERNG DEDOGNIC	
1.		REPORTING PERSONS TIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
2.		ISTER FUND L.P. E APPROPRIATE BOX IF A MEMBER OF A GROUP	
۷.	(see instruct		
	(a)		
3.	(b) SEC USE O	NLY	
٥.	220 COL O	·· ··	
4.	CITIZENSE	IIP OR PLACE OF ORGANIZATION	_
	CAYMAN I	SLANDS	
		5. SOLE VOTING POWER	
		0	
		6. SHARED VOTING POWER	
NUN	MBER OF	672,756 shares of Common Stock	
SF	HARES	5,405,348 shares of Common Stock issuable upon conversion of Preferred Stock	
	FICIALLY NED BY	2,512,383 shares of Common Stock issuable upon exercise of warrants SOLE DISPOSITIVE POWER	
E	EACH	/. SOLE DISPOSITIVE FOWER	
	ORTING ON WITH	0	

		672,756 shares of Common Stock 5,405,348 shares of Common Stock issuable upon conversion of Preferred Stock 2,512,383 shares of Common Stock issuable upon exercise of warrants	
9.	AGGREGA	ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
۶.			
	5,405,348 s	ares of Common Stock shares of Common Stock issuable upon conversion of Preferred Stock hares of Common Stock issuable upon exercise of warrants	
10.	CHECK IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(see instruct	tions)	
11.	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	9.9%1		
12.	TYPE OF R	REPORTING PERSON (see instructions)	
	PN		
CLICI	P No. 15117F	2500 13G/A	Page 6 of 10 Pages
CO31	1 No. 1311/F	150/A	rage of or rollages
1.	NAMES OF	F REPORTING PERSONS	
	I.R.S. IDEN	ITIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
2.		pportunities Fund I L.P. HE APPROPRIATE BOX IF A MEMBER OF A GROUP	
۷.	(see instruct		
	(a) □ (b) □		
3.	SEC USE O	ONLY	
4.	CITIZENSI	HIP OR PLACE OF ORGANIZATION	
	CAYMAN	ISLANDS	
		5. SOLE VOTING POWER	
		0	
	ADED OF	6. SHARED VOTING POWER	
	MBER OF HARES	815,644 shares of Common Stock	-
	EFICIALLY NED BY	1,271,585 shares of Common Stock issuable upon conversion of Preferred Stock 659,340 shares of Common Stock issuable upon exercise of warrants	
	EACH	7. SOLE DISPOSITIVE POWER	
	PORTING SON WITH	0	
LIC	JOIN WITH	8. SHARED DISPOSITIVE POWER	
		815,644 shares of Common Stock	
		1,271,585 shares of Common Stock issuable upon conversion of Preferred Stock 659,340 shares of Common Stock issuable upon exercise of warrants	:
		037,340 shares of Common stock issuable upon exercise of warrants	
9.	AGGREGA	ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,271,585	hares of Common Stock shares of Common Stock issuable upon conversion of Preferred Stock shares of Common Stock issuable upon exercise of warrants	
10.		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11.	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.5%1		
12.		REPORTING PERSON (see instructions)	

8. SHARED DISPOSITIVE POWER

CUSIP No. **15117F500** Page 7 of 10 Pages

Item 1.

- (a) Name of Issuer: CELLECTAR BIOSCIENCES, INC.
- (b) Address of Issuer's Principal Executive Offices 100 Campus Drive, Florham Park, New Jersey 07932

Item 2.

(a) Name of Person Filing
Rosalind Advisors, Inc. ("Advisor" to RMF and ROFI)
Rosalind Master Fund L.P. ("RMF")
Rosalind Opportunities Fund 1 LP ("ROFI")
Steven Salamon ("President")
Steven Salamon is the portfolio manager of the Advisor which advises RMF.
Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

(b) Address of the Principal Office or, if none, residence Rosalind Advisors, Inc. and Rosalind Opportunities Fund I L.P. 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada

Rosalind Master Fund L.P. P.O. Box 309 Ugland House, Grand Cayman KY1-1104, Cayman Islands

Steven Salamon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada

Gilad Aharon 15 Wellesley Street West Suite 326 Toronto, Ontario M4Y 0G7 Canada

- (c) The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P.
- (d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:			
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).	
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).	
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).	
(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);	
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);	
(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);	
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);	
(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).	
Item 4.	Owr	nership.	
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.			
(a)	Am	ount beneficially owned:	
	Ros	salind Master Fund L.P. is the record owner of 1,488,400 shares of common stock.	
	helo	salind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares d by RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial ner of shares held by RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial nership of the shares.	
(b)	Per	cent of class:	
		Rosalind Advisors, Inc. – 9.9%	
		Rosalind Master Fund L.P. – 9.9%	
		Rosalind Opportunities Fund I L.P. 8.5%	
		Steven Salamon – 9.9%	
		Gilad Aharon – 9.9%	

(c) Number of shares as to which the person has:

(i) Shared power to vote or to direct the vote

Rosalind Advisors, Inc. – 1,488,400 Rosalind Master Fund L.P. – 672,756 Rosalind Opportunities Fund I LP–815,644

Steven Salamon – 1,488,400 Gilad Aharon - 1,488,400

(ii) Sole power to dispose or to direct the disposition of

Gilad Aharon - 3,900

(iii) Shared power to dispose or to direct the disposition of

Rosalind Advisors, Inc. – 1,488,400 Rosalind Master Fund L.P. – 672,756 Rosalind Opportunities Fund I LP–815,644

Steven Salamon – 1,488,400 Gilad Aharon - 1,488,400

Instruction. For computations regarding securities which represent a right to acquire an underlying securitysee §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Item 7 - 9. Not Applicable

CUSIP No. **15117F500** 13G/A Page of 10 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

2/14/2024 Date

Signature

Steven Salamon/President Rosalind Advisors, Inc. Name/Title

Exhibit A

Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Cellectar Biosciences, Inc. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc. By:
Name: Steven Salamon
Title: President
Rosalind Master Fund L.P.
By:
Name: Mike McDonald
Title: Director, Rosalind (Cayman) Ltd. (as General
Partner to Rosalind Master Fund)
By:
Name: Steven Salamon

Exhibit A

Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Cellectar Biosciences, Inc. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc.
Ву:
Name: Steven Salamon
Title: President
Rosalind Master Fund L.P.
By:
Name: Mike McDonald
Title: Director, Rosalind (Cayman) Ltd. (as General
Partner to Rosalind Master Fund)
Ву:
Name: Steven Salamon